Cisplatin, Epirubicin and Uracil-Tegafur Combination in Metastatic Gastric Cancer: Retrospective Evaluation

Purpose: Gastric cancers are one of the most common malignancies worldwide. Surgery, radiotherapy and chemotherapy are used in treatment alone or as combination. The aim ofthis study was to evaluate retrospectively the effectiveness of cisplatin, epirubicin, uracil-tegafur combination in gastric cancer. Material and Methods: A total of 20 patients were included who have histopatolagically proven gastric cancer with measurable metastasis by screening methods. Chemotherapy regimen consists of epirubicin 50mg/m^2 1. day, cisplatin 60g/m^2 1.day, uracil-tegafur 300mg/m^2 2 weeks on, 1 weeks off in 3 weeks interval. Response rate, overall survival and toxicities were evaluated. Results: Twenty patients were included in the analysis (15 men, 5 women ,median age 55 years). Most common metastatic side was liver (%55). Totally 94 cycles chemotherapy were given which median cycles of five. Overall response rate was %25 and clinical benefit rate was %65. Overall survival and progression free survival was 8 months and 5 months respectively. Most common side effect were nausea and vomiting (%65), fatigue (%60) and anemia (%60). Conclusion: Epirubicin, cisplatin, uracil-tegafur combination has moderate effect in gastric cancer. Combination chemotherapy was well tolerated with acceptable side effect.